Quality of life of people with CKD (QuiCK) study
The quality of life of people with CKD is significantly impaired. Depression, fear and anxiety have been reported in this population. Relatively few Australian studies have evaluated the quality of life of patients with CKD. No studies have assessed the quality of life of patients with CKD and other co-morbidities such as cancers and cardiovascular disease.
Cancer screening and early detection with effective treatment of early stage cancer is an attractive way to prevent the development of advanced-stage cancers. However, recent cost-effectiveness analyses of cancer screening in the dialysis and transplant populations reported substantial uncertainties regarding the quality of life of people with CKD and cancer(4;5).
In addition, health outcomes were assessed in natural units rather than using utilities terms such as quality-adjusted life years in these analyses. Utilities are a set of values or weights assigned to each particular health outcome state. Given the methods used in utility measurements include a personal choice-based preference weighting between 0 (worst health state) and 1 (best health state) in the formula, they give a more realistic evaluation of the true impact on the survival and quality of life in the specified population.
There is to date, no available data specifically assessing the quality of life (QoL) of having cancer in the transplant and end-stage kidney disease population. Our study will be the first to assess the QoL of people with CKD and their perception of cancer risk/screening/prevention from a qualitative perspective. Using utilities-based measurements, we are also incorporating and valuing the different health outcomes according to their desirability, adjusting for both the overall survival and quality of life in this population.
The aims of this study are:
- To evaluate the quality of life of people with CKD and cancer
- To explore their perceptions and understanding about their risk and prognoses of cancer, cancer screening and preventive strategies
- To measure the utility-based QoL for the different stage-dependent health outcomes states of cancers in the kidney transplant and end-stage kidney diseases population
- To determine whether there is a difference in the cancer utility scores between transplant and dialysis patients and to assess the extent of such differences in these two populations
- To investigate the relationship and correlation between utility-based QoL measures and generic QoL health measures